



Universiteit  
Leiden  
The Netherlands

## **Human pharmacology of current and new treatments for schizophrenia**

Liem-Moolenaar, M.

### **Citation**

Liem-Moolenaar, M. (2012, March 8). *Human pharmacology of current and new treatments for schizophrenia*. Retrieved from <https://hdl.handle.net/1887/18570>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/18570>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/18570> holds various files of this Leiden University dissertation.

**Author:** Liem-Moolenaar, Marieke

**Title:** Human pharmacology of current and new treatments for schizophrenia

**Issue Date:** 2012-03-08



# HUMAN PHARMACOLOGY OF CURRENT AND NEW TREATMENTS FOR SCHIZOPHRENIA

PROEFSCHRIFT

ter verkrijging van de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. mr. P. F. van der Heijden,  
volgens besluit van het College voor Promoties,  
te verdedigen op donderdag 8 maart 2012  
klokke 16:15 uur

DOOR

Marieke Liem-Moolenaar,  
geboren te Nijmegen  
in 1974

## PROMOTIECOMMISSIE

### PROMOTORES

Prof. dr. J.M.A. Van Gerven (*promotor*)

Prof. dr. A.F. Cohen (*promotor*)

Dr. K.L. Franson (*co-promotor*), Associate Dean for Professional Education,  
Department of Clinical Pharmacy University of Colorado School of Pharmacy,  
Denver, United States

### OVERIGE LEDEN:

Prof. dr. A.C.G. Egberts, *hoogleraar klinische farmacie Universiteit Utrecht,*  
*Universitair Medisch Centrum Utrecht*

Prof. dr. R.S. Kahn, *hoogleraar klinische en biologische psychiatrie Universiteit*  
*Utrecht, Universitair Medisch Centrum Utrecht*

Prof. dr. F.G. Zitman

### DESIGN

C de Lint, Voorburg (caro@delint.nl)

### ACKNOWLEDGEMENTS

The publication of this thesis was financially supported by the foundation Centre for  
Human Drug Research (CHDR), Leiden, the Netherlands

*Copyright for the cover pictures was requested and approved by the authors and the journal which  
printed the original picture (Nature 2011, 473: 221-5)*

10	CHAPTER 1 Introduction
56	CHAPTER 2 Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT <sub>6</sub> antagonist SB742457 (repeated doses) in healthy men
80	CHAPTER 3 Psychomotor and cognitive effects of of talnetant (SB223412) in healthy volunteers compared to placebo or haloperidol
106	CHAPTER 4 Early stage development of the glycine-1 reuptake inhibitor SCH 900435: Central nervous system effects compared to placebo in healthy men
148	CHAPTER 5 The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects
172	CHAPTER 6 The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects
190	CHAPTER 7 Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects
218	CHAPTER 8 Central nervous system effects of haloperidol on THC in healthy male volunteers
248	CHAPTER 9 General discussion and conclusions
264	Samenvatting/Summary in Dutch
275	Curriculum Vitae
277	Nawoord
279	List of publications

## LIST OF ABBREVIATIONS

5-HT	5-hydroxytryptamine; serotonin
AD	Alzheimer's disease
AE	Adverse event
AMPA	2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
APA	American Psychiatric Association
AUC	Area under the plasma concentration-time curve
BMI	Body Mass Index
C <sub>MAX</sub>	Maximal mean plasma concentration
CATIE	Clinical Antipsychotic Trials of Intervention Effectiveness
CB	Cannabinoid
CBD	Cannabidiol
CI	Confidence Interval
CL	Total clearance of drug from plasma
CNS	Central Nervous System
COMT	Catechol-O-methyl transferase
CYP	Cytochrome P450
D <sub>1</sub>	Dopamine-1 receptor
D <sub>2</sub>	Dopamine-2 receptor
DA	Dopamine
DSM	Disease State Manual
ECG	Electrocardiogram
EEG	Electroencephalogram
EPS	Extrapyramidal side effects
FGA	First-generation antipsychotics
FSH	Follicle-Stimulating Hormone
GABA	Gamma-aminobutyric acid
GlyT <sub>1</sub>	Glycine transporter 1
H <sub>1</sub>	Histamine-1 receptor
HPLC/MS/MS	High performance chromatography/mass spectrometry
K <sub>d</sub>	Affinity
LH	Luteinizing Hormone
LLQ	Lower Limit of Quantification
LSM	Least Square Mean
LSD	Lysergic acid diethylamide
NA	Nucleus Accumbens
NK3	Neurokinin-3 receptor
NMDA	N-methyl-D-aspartate
PANSS	Positive and Negative Syndrome Scale
PK	Pharmacokinetics
PD	Pharmacodynamics
SAE	Serious Adverse Event
SGA	Second-generation antipsychotics
SPV	Saccadic Peak Velocity
SSRI	Selective Serotonin Reuptake Inhibitors
T <sub>1/2</sub>	Elimination half life
THC	Δ <sup>9</sup> -tetrahydrocannabinol
T <sub>MAX</sub>	Time to maximal plasma drug concentration
VAS	Visual Analogue Scales
VTA	Ventral Tegmental Area
VVLT	Visual Verbal Learning Test